Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.
Phase:
PHASE4
Details
Lead Sponsor:
Heart Center Research, LLC
Collaborator:
Boston Scientific Corporation
Treatments:
Bumetanide Furosemide Hydralazine Isosorbide Dinitrate sacubitril and valsartan sodium hydrate drug combination Torsemide